Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.20 -2.35% 8.30 8.20 8.40 8.60 8.30 8.60 517,395 16:18:06
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.2 -2.1 - 23

Evgen Pharma PLC Posting of Circular & Notice of GM

12/02/2021 7:00am

UK Regulatory (RNS & others)


Evgen Pharma (LSE:EVG)
Historical Stock Chart


From Jan 2021 to Apr 2021

Click Here for more Evgen Pharma Charts.

TIDMEVG

RNS Number : 8624O

Evgen Pharma PLC

12 February 2021

Evgen Pharma plc

("Evgen Pharma" or "the Company")

Posting of Circular

and

Notice of General Meeting

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, announces that further to its announcement of the proposed Fundraising on 2 February 2021 (the " Placing Announcement "), a Circular, including the notice of General Meeting, a Form of Proxy and (where applicable) an Open Offer Application Form are today being posted to shareholders. The General Meeting will be held at 10:00 a.m. on 3 March 2021.

In light of the current restrictions in place with respect to the COVID-19 pandemic and, in particular, the UK Government's response (including guidance on working from home in place at the date of this notice), the Company's Board of Directors have concluded that the General Meeting will be held as a closed meeting. The Company will make arrangements such that the legal requirements to hold the General Meeting can be satisfied through the electronic attendance of the minimum number of shareholders, drawn from members of the Board. No other shareholder will be able to attend the General Meeting and are, instead, requested to complete the Form of Proxy, appointing the chairman of the meeting, rather than a third party, as their proxy by the relevant time.

Copies of the Circular and Form of Proxy will be made available on the Company's website www.evgen.com .

Capitalised terms used in this announcement shall have the same meanings as the definitions in the Placing

Announcement   unless otherwise defined herein . 

Enquiries:

 
 Evgen Pharma plc                                                         Via Walbrook 
  Barry Clare, Chairman 
  Dr Huw Jones, CEO 
  Richard Moulson, CFO 
 finnCap 
  Geoff Nash / Teddy Whiley (Corporate 
  Finance) 
  Alice Lane / Sunila de Silva 
  (ECM) 
  www.finncap.com                                                 +44 (0) 20 7220 0500 
 Walbrook PR                              +44 (0)20 7933 87870 or evgen@walbrookpr.com 
  Paul McManus/ Anna Dunphy                          +44 (0)7980 541 893 / +44 (0)7876 
                                                                               741 001 
 

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

Clinical data from the Company's open-label Phase II STEM trial has shown that SFX-01 can halt the growth of progressing tumours in patients with oestrogen-positive (ER+) metastatic breast cancer, and in some cases significantly shrink the tumour, whilst causing very few side effects.

The Company commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.

For further information, please visit: www.evgen.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOGTBMFTMTJBBPB

(END) Dow Jones Newswires

February 12, 2021 02:00 ET (07:00 GMT)

1 Year Evgen Pharma Chart

1 Year Evgen Pharma Chart

1 Month Evgen Pharma Chart

1 Month Evgen Pharma Chart
ADVFN Advertorial
Your Recent History
LSE
EVG
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210413 00:56:10